CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
FOLFOX regimen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03861702
NCT03861702Phase 2Completed
CompareCT.gov

A Phase II Study to Evaluate the Efficacy of Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067

Nelson Yee·interventional·Posted Mar 4, 2019·Updated Apr 18, 2025

In Brief

A Phase 2 clinical trial evaluating FOLFOX regimen and Liposomal Irinotecan for Locally Advanced Pancreatic Carcinoma(LAPC). Completed, enrolled 28 participants across 4 sites.

Detailed Summary

This is a phase II, single-arm, open-label, clinical study to investigate the efficacy and tolerability of a combination of liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced pancreatic carcinoma (LAPC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced Pancreatic Carcinoma(LAPC)
CountriesUnited States
CollaboratorsIpsen

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 4, 2019
Enrollment StartSep 2, 2020
Primary CompletionAug 16, 2023
Study CompletionSep 27, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 7.3 years ago

Interventions

FOLFOX regimendrug

FOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil)

Liposomal Irinotecandrug

Liposomal Irinotecan